NEW YORK, NY / ACCESSWIRE / July 8, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) with a price target of $4.52.
The report is available here: RGRX Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.
RegeneRx Biopharmaceuticals, Inc. ("RGRX") is a Maryland-based clinical-stage biopharmaceutical company that focuses on the design, research and development of drugs based on a peptide, Thymosin beta 4 (Tβ4), which targets diseases with unmet medical needs. RGN-259, RGN-352, and RGN-137 are three product candidates currently under clinical development.
"With a worldwide market opportunity of $4.4 billion and growing needs from China because of significant pollution, RGN-259 will potentially gain a large share in the dry-eye treatment market. As no effective drug currently available for NK, RGN-259 is highly likely to become the first one to tap the $500 million market worldwide. We are expecting RegeneRx to commercialize RGN-259 in 2018," stated Ajay Tandon, CEO of SeeThruEquity. "We are initiating coverage with a 12-month price target of $4.52 per share."
Additional highlights from the report are as follows:
Thymosin beta 4 (Tβ4) has wide clinical applications
Tβ4 is a novel therapeutic peptide that can be used as a wound healing, repair, and tissue regenerating factor. It has multiple biologic activities, including reducing inflammation, accelerating collagen deposition, regulating laminin-5 production and promoting cell survival and migration, etc. Numerous preclinical studies have shown that Tβ4 is a potential treatment for ophthalmic, cardiac, central nervous system, peripheral nervous system, and dermal disorders. Currently RegeneRx is the only company developing major product candidates and pursuing some other derivatives of Tβ4.
Unmet medical needs with huge market opportunities
RGN-259 is a novel eye drop to treat dry eye and neurotrophic keratitis (NK) through regeneration of corneal tissue. To date Restasis(R) is the only available product for dry eye with annual sales of around $1 billion. Compared with Restasis(R), RGN-259 repairs tissue and therefore leads to quicker efficacy and causes no burning and visual blurring to patients. With a worldwide market opportunity of $4.4 billion and growing needs from China because of severe pollution, RGN-259 will certainly gain a large share in the dry-eye treatment market. As no effective drug is currently available for NK, RGN-259 is highly likely to become the first one to tap the $500 million market. We are expecting RegeneRx to commercialize RGN-259 in 2018. RGN-352 treats cardiovascular and nervous system diseases. As no approved pharmaceutical products are currently available for regenerating cardiac and nervous tissue, RGN-352 has a potential market size of approximately $41.4 billion around the world. We are expecting RegeneRx to commercially launch RGN-352 in 2021.
Strategic partnerships help expand market in APAC, EU and the U.S.
RGRX has partnered with major pharmaceutical companies in the APAC, EU, and the U.S. to facilitate product candidate development and commercialization since 2004. Sigma-Tau Group (now Alfa Wassermann) is responsible for developing and marketing RGN-352 and RGN-137 in EU, Lee's Pharmaceuticals for RGN-259, RGN-352 and RGN-137 in China, Hong Kong, Macau, and Taiwan, and G-treeBNT for RGN-259 in Asia uncovered by Lee's and RGN-137 in the U.S. ReGenTree, a JV formed with G-treeBNT, will develop and commercialize RGN-259 in the U.S. As RGRX assumes no financial obligation in these strategic partnerships, we believe it will significantly boost its value after products are commercially launched.
Please review important disclosures on our website at www.seethruequity.com.
About RegeneRx Biopharmaceuticals, Inc.
RegeneRx Biopharmaceuticals, Inc. is a clinical stage company that focuses on developing Thymosin beta 4 for tissue and organ protection, repair and regeneration. Tβ4 has numerous clinical applications in ophthalmic, cardiac, central and peripheral nervous system, and dermal disorders. RegeneRx formulates Tβ4 into RGN-259, RGN-352, and RGN-137 that target diseases with unmet medical needs. It has partnered with Sigma-Tau (now Alfa Wassermann), Lee's Pharmaceuticals and G-treeBNT and formed the ReGenTree JV to develop and commercialize its product candidates in Asia-Pacific, Europe, and the U.S.
For more information on the company and its product candidates, please visit www.RegeneRx.com.
About SeeThruEquity
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.
For more information visit www.seethruequity.com.
Contact:
Ajay Tandon
SeeThruEquity
info@seethruequity.com
SOURCE: SeeThruEquity